drugset / Trial / NCT05405595
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
RandomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1b/2, open-label, dose escalation, dose expansion and dose optimization study to evaluate the safety, tolerability, PK, and immunogenicity of ADG126-pembrolizumab combination regimens in patients with advanced/metastatic solid tumors. The study drug ADG126 is an anti-CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. Pembrolizumab is a PD-1 receptor-blocking antibody (a humanized IgG4 monoclonal antibody).
Timeline
- Start
- 2022-06-15
- Primary completion
- 2026-10-31
- Completion
- 2027-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Muzastotug | Monoclonal antibody | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Background | Bevacizumab | Monoclonal antibody | — | — |
| Background | Fruquintinib | Small molecule | — | Oral |
| Background | Tipiracil | Small molecule | — | — |
| Background | Trifluridine | Small molecule | — | — |
Indications
No indication recorded.